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Abstract
Objectives
The objective was to identify the systematic associations among chronic diseases and
drugs in the form of patterns and to describe and clinically interpret the constituted patterns
with a focus on exploring the existence of potential drug-drug and drug-disease interactions
and prescribing cascades.
Methods
This observational, cross-sectional study used the demographic and clinical information
from electronic medical databases and the pharmacy billing records of all users of the public
health system of the Spanish region of Aragon in 2015. An exploratory factor analysis was
conducted based on the tetra-choric correlations among the diagnoses of chronic diseases
and the dispensed drugs in 887,572 patients aged�65 years. The analysis was stratified by
age and sex. To name the constituted patterns, assess their clinical nature, and identify
potential interactions among diseases and drugs, the associations found in each pattern
were independently reviewed by two pharmacists and two doctors and tested against the lit-
erature and the information reported in the technical medicinal forms.
Results
Six multimorbidity-polypharmacy patterns were found in this large-scale population study,
named as respiratory, mental health, cardiometabolic, endocrinological, osteometabolic,
andmechanical-pain. The nature of the patterns in terms of diseases and drugs differed by
sex and age and becamemore complex as age advanced.
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Conclusions
The six clinically soundmultimorbidity-polypharmacy patterns described in this non-elderly
population confirmed the existence of systematic associations among chronic diseases and
medications, and revealed some unexpected associations suggesting the prescribing cas-
cade phenomenon as a potential underlying factor. These findingsmay help to broaden the
focus and orient the early identification of potential interactions when caring for multimorbid
patients at high risk of adverse health outcomes due to polypharmacy.
Introduction
Optimization of drug prescribing is emerging as a mandatory element for healthcare systems
[1]. Prescribing is largely based on single-disease evidence-based guidelines, which do not gen-
erally consider chronic multimorbidity (i.e., co-occurrence of several chronic diseases within a
patient). Consequently, patients are prescribed several drugs following multiple disease-spe-
cific guidelines [2].
The resulting polypharmacy, defined as the use of multiple medicines, is not always appro-
priate. Several studies have shown that inappropriate polypharmacy increases the risk of
unnecessary drug use, potential drug-drug and drug-disease interactions, and adverse drug
reactions (ADRs) [3–5]. Polypharmacy is often due to the so-called ‘prescribing cascade’,
which involves the clinician’s failure to recognize a new medical event as an ADR. In such
cases, an additional drug is prescribed to treat the adverse reaction leading to side effects
instead of withdrawing or changing the responsible drug, thus creating a vicious circle and
adding further risks to multimorbid patients [6–7].
Large-scale population studies aiming to explore real-life patterns of polypharmacy repre-
sent a unique opportunity to analyse the complexity of drug prescribing, and explore the exis-
tence of systematic associations among drugs. A recent study identified several polypharmacy
patterns in a large population, and their clinical interpretation suggested the existence of
underlying causal factors that were often related, not to the disease itself, but to the side effects
of the prescribed treatments. The study highlighted the need for analyses combining diseases
and drugs, as both can be causal and consequent factors of inappropriate drug prescription
[8]. Although the burden of chronic diseases and drugs prescribed, and subsequently the risk
of interactions among them, increases with age, this problem is not exclusive to the elderly,
and research should also focus on younger populations to allow the early identification of
potential interactions and the development of prevention strategies.
This large-scale population study aimed to characterize the existence of systematic associa-
tions among chronic diseases and drugs in the form of patterns in young and adult populations
and to describe and clinically interpret the constituted patterns with a focus on exploring the
existence of potential drug-drug and drug-disease interactions and prescribing cascades.
Materials andmethods
Study design, data sources, and study population
We conducted a cross-sectional, observational study in the EpiChron Cohort [9] using data
from 2015. This cohort integrates anonymized demographic, clinical and drug dispensation
information of all users of the public health system in Aragon, a region of north-eastern Spain
(1,144,816 inhabitants in 2015).
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Patients aged>65 years were excluded from the study to allow focus on young and adult pop-
ulations. Furthermore, preliminary tests conducted in the elderly revealed that a high number of
diseases and drugs present multicollinearity (i.e., linear correlation), leading to the creation of a
singular data matrix that invalidates the use of factor analysis. The study population included
887,572 patients, who were stratified into three age groups: 0–14, 15–44, and 45–65 years.
We considered demographic variables (i.e., age and sex), diagnoses of chronic diseases
from primary care and hospitals, and dispensed drugs during 2015 from pharmacy billing rec-
ords. Diagnoses were originally coded according to the International Classification of Primary
Care (ICPC) and to the International Classification of Diseases, 9th Revision (ICD-9), and
were grouped in the Expanded Diagnostic Clusters (EDC) of the Johns Hopkins ACG System
(version 11.0, The Johns Hopkins University, Baltimore, MD, US). All 114 diseases classified
as chronic by Salisbury et al [10] were included in the analysis and coded in binary format (i.e.,
absence/presence of the disease). Additionally, we included rhinitis, according to the recent
World Health Organization (WHO) indications [11], and acute lower respiratory tract infec-
tion, as it can lead to chronic sequelae. Drugs were coded according to the Anatomical Thera-
peutic Chemical Classification (ATC) System at the third level to facilitate data processing,
also in binary format.
The study was approved by the Clinical Research Ethics Committee of Aragon (CEICA),
which waived the requirement for patient consent since data of the EpiChron Cohort are
anonymized, and no interventions on individuals were performed.
Statistical analysis
A descriptive analysis of the population was performed by calculating the frequencies of
chronic conditions and drugs dispensed in each sex and age group.
Multimorbidity and polypharmacy patterns were identified using exploratory factor analysis
based on a correlation matrix to determine which diagnoses and dispensed drugs comprised
each pattern. This technique was previously used to cluster chronic conditions [12] and medica-
tions [8] separately. We used tetra-choric correlation matrices due to the dichotomous nature
of both chronic diagnoses and dispensed drugs. Factor extraction was performed using the prin-
cipal factor method. An oblique rotation (Oblimin) was applied to facilitate factor interpreta-
tion. We used scree plots to determine the number of factors to be extracted in each group.
When a clear solution was not obtained by the scree plot, a clinical evaluation of different solu-
tions was conducted by EM, FGR, and MAPS. To determine which EDCs and ATC codes
formed each pattern we selected those with scores�0.30 for each factor, which is the threshold
factor loading traditionally used when deciding wheter to accept a variable as belonging to a fac-
tor [13]. EDCs and ATC codes with scores from 0.25–0.30 were included in a factor if consid-
ered relevant and useful in the clinical explanation of the pattern [8]. The factors resulting from
this analysis were interpreted as multimorbidity and polypharmacy patterns.
To increase the epidemiological interest of the study, we included in the analysis only EDCs
with a prevalence�1–2% in each age and sex group. Likewise, ATC codes with a prevalence
�3–5% in each subgroup were considered for analysis. Some ATCs with lower prevalence
were also included based on their potential relevance for interactions or side effects. In con-
trast, several ATC codes presented multicollinearity with specific EDCs and were discarded to
allow statistical analysis. In these cases, ATC codes were manually excluded in the order of the
degree of multicollinearity until the factor analysis gave satisfactory results. The list of dis-
pensed drugs was reviewed by two pharmacists (EM, MAPS) and one general practitioner
(FGR). Final inclusion and exclusion criteria of EDCs and ATC codes are specified for each
sex and age group.
Multimorbidity and polypharmacy patterns
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In children aged 0–14 years, EDCs with a prevalence�1% and ATC codes with a preva-
lence�3% were included, except for vitamins A and D, including combinations of the two.
Propulsives, decongestants and antiallergics, psychostimulants, agents used for attention-defi-
cit hyperactivity disorder (ADHD) and nootropics, drugs for peptic ulcer and gastro-esoph-
ageal reflux disease, and antiepileptics, were also included regardless of their prevalence based
on their potential to cause ADRs.
In patients aged 15–44 years, EDCs with a prevalence�2% and ATC codes with a preva-
lence�3% were included, except for lipid modifying agents due to collinearity with disorders
of lipid metabolism. Antiepileptics, antipsychotics, corticosteroids for systemic use, thyroid
preparations, opioids, anti-inflammatory agents and anti-infective in combination, antithrom-
botic agents, and antimigraine preparations, were included regardless of their prevalence.
For women aged 45–65 years, EDCs with a prevalence�2% and ATC codes with a preva-
lence�5% were included, except for lipid modifying agents, thyroid preparations and iron
preparations, due to collinearity with disorders of lipoid metabolism, thyroid disease, iron
deficiency and other deficiency anaemias, respectively. For men aged 45–65 years, the same
inclusion criteria were used, but lipid modifying agents, blood glucose lowering drugs exclud-
ing insulins, angiotensin-converting enzyme inhibitors, combinations of angiotensin II antag-
onist, beta blocking agents, and antigout preparations, were excluded due to collinearity with
disorders of lipoid metabolism, diabetes, hypertension, and gout.
Sample adequacy was evaluated using the Kaiser-Meyer-Olkin (KMO) test. Only values
>0.60 were considered as acceptable. Additionally, as a measure of the model’s goodness-of-
fit, we calculated the proportion of cumulative variance, which describes the data variability
explained by the patterns. All statistical analyses were conducted in STATA (Version 12.0, Sta-
taCorp LLC, College Sation, TX, US).
Denomination and clinical nature of the patterns
To assess the clinical nature of the patterns identified by statistical criteria, and to identify
potential interactions among diseases and drugs within the patterns, three consecutive steps
were followed. First, the associations found in each pattern were independently reviewed by
two pharmacists (EM and MAPS) and two doctors (FGR and APT) from the research team
and with proven expertise to look for potential inappropriate medication, prescribing cascade,
and drug-drug, drug-disease, and disease-disease interactions. Second, a consensus meeting
was held to discuss and resolve discrepancies and to name the patterns based on their clinical
nature. Third, the findings were tested against the literature and the information reported in
the technical medicinal forms.
Results
The mean number of concomitant diseases increased with age, from one condition registered
in children aged 0–14 years to almost three conditions in adults aged 45–65 years (Table 1).
The number of dispensed drugs followed the same trend and increased from two medications
in children to almost four dispensations in adults aged 45–65.
Multimorbidity and polypharmacy patterns
Six different patterns of multimorbidity and polypharmacy were identified in the study popu-
lation, named respiratory, mental health, cardiometabolic, endocrinological, osteometabolic,
and mechanical pain, according to their clinical nature. Respiratory, mental health, and cardi-
ometabolic patterns occurred in both men and women. Endocrinological and osteometabolic
patterns appeared only in women, whereas the mechanical pain pattern appeared exclusively
Multimorbidity and polypharmacy patterns
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in men (Table 2). Three different variants were described in the respiratory pattern: a generic
one, a pattern with acute infection, and a respiratory pattern with an asthma-allergic compo-
nent. The nature of the patterns in terms of diseases and drugs differed depending on sex and
age. The patterns found in each age and sex group are described below. The scree plots are
reported in S1 and S2 Figs and the factor scores in S1 Table.
Boys aged 0–14 years. This age and sex group had a KMO sampling adequacy index of
0.740. The proportion of cumulative variance explained by the patterns was 0.356. The scree
plot and clinical evaluation indicated the extraction of three factors (Table 3). Factor 1 clus-
tered acute respiratory infection and a pharmacological pattern for the symptomatic treatment
with corticoids, inhaled beta-adrenergic agonists, antipyretics, antihistamines, and nonsteroi-
dal anti-inflammatory drugs (NSAIDS). Antibiotics (i.e., macrolides and penicillin antibiotics)
could be present to treat the potential bacterial superinfection [8]. The potential therapeutic
cascades identified in this pattern were: a) antifungal drugs for the treatment of candidiasis
secondary to antibiotics [8] and corticoids inhalers [14]; b) electrolytes for the treatment of
gastroenteritis dehydration after use of antibiotics [14]; and c) anxiolytics, supposedly pre-
scribed for the symptomatic treatment of the potential side effects of adrenergic inhalants (e.g.,
tachycardia, hyperactivity, and insomnia) dispensed for the symptomatic treatment of acute
respiratory infection [14]. As potential drug-drug interactions (DDIs) we observed the com-
bined use of NSAIDs and corticoids [15].
Table 1. Mean number of chronic diseasesa and dispensed drugsb according to age and sex groups.
Women Men Total
0–14 years N (%) 78,534 (8.85) 82,893 (9.34) 161,427 (18.2)
Chronic diseases (95% CI) 1.00 (1.00–1.01) 1.12 (1.11–1.12) 1.06 (1.05–1.07)
Dispensed drugs (95% CI) 2.16 (2.15–2.18) 2.27 (2.26–2.29) 2.22 (2.21–2.23)
15–44 years N (%) 205,122 (23.1) 190,658 (21.5) 395,780 (44.6)
Chronic diseases (95% CI) 1.47 (1.46–1.47) 1.14 (1.14–1.15) 1.31 (1.31–1.32)
Dispensed drugs (95% CI) 2.67 (2.66–2.68) 1.78 (1.77–1.78) 2.24 (2.23–2.25)
45–65 years N (%) 168,587 (19.0) 161,778 (18.2) 330,365 (37.2)
Chronic diseases (95% CI) 3.06 (3.04–3.07) 2.48 (2.47–2.49) 2.77 (2.76–2.78)
Dispensed drugs (95% CI) 4.34 (4.32–4.36) 3.42 (3.41–3.44) 3.89 (3.88–3.90)
Total N (%) 452,243 (51.0) 435,329 (49.0) 887,572 (100)
Chronic diseases (95% CI) 1.98 (1.97–1.98) 1.63 (1.63–1.64) 1.81 (1.81–1.81)
Dispensed drugs (95% CI) 3.20 (3.19–3.21) 2.48 (2.47–2.49) 2.85 (2.84–2.86)
Abbreviations: CI, confidence interval; N, number of patients.
a According to Salisbury et al.; rhinitis and acute lower respiratory tract infection were also included.
b ATC (Anatomical Therapeutic Chemical Classification) codes at the third level.
https://doi.org/10.1371/journal.pone.0210701.t001
Table 2. Multimorbidity and polypharmacy patterns identified in each age and sex group.
0–14 years 15–44 years 45–65 years
Women Respiratory-acute infection Mental health Mental health
Respiratory-asthma-allergic Respiratory Respiratory
Mental health Endocrinological Cardiometabolic
Osteometabolic
Men Respiratory-acute infection Mental health Mental health
Respiratory-asthma-allergic Mechanical pain Cardiometabolic
Mental health Respiratory Respiratory
https://doi.org/10.1371/journal.pone.0210701.t002
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Factor 2 clustered a respiratory-allergic pattern comprising asthma and allergic rhinitis
with medications such as antihistamines, antiallergics, decongestants, other nasal preparations
for topical use and beta-adrenergic agonists.
Factor 3 clustered developmental, psychosocial disorders and ADHD to drugs for the treat-
ment of these diseases, such as psychostimulants, agents used for ADHD and antiepileptics.
This pattern also included an unexpected association with proton pump inhibitors (PPIs),
which are drugs for the treatment of peptic ulcers. PPIs might have been used to prevent upper
gastrointestinal tract bleeding or gastroesophageal reflux disease due to the use of antidepres-
sants [8,16,17]. Potential DDIs observed in this pattern were: a) the combined use of carba-
mazepine and methylphenidate [14]; and b) carbamazepine and omeprazole [18].
Men aged 15–44 years. This age and sex group had a KMO sampling adequacy index of
0.751. The proportion of cumulative variance explained by the patterns was 0.370. The scree
plot for this group indicated that the number of factors to be extracted was equal to three
(Table 4). Factor 1 clustered psychopathological processes (e.g., depression, anxiety, sleep dis-
orders, psychosis, and neurosis and substance use) and drugs including antidepressants, anxio-
lytics, antiepileptics and antipsychotics. A potential interaction identified in this pattern was
Table 3. Patterns of chronic diseases (EDC codes) and drugs (ATC codes) and loading factor scores in boys aged 0–14 years. Diseases are highlighted in bold.
EDC/ATC Disease/Drug Factor 1 Factor 2 Factor 3
H02A Corticosteroids for systemic use, pain 0.6877
RES02 Acute lower respiratory tract infection 0.6748
R03A Adrenergics, inhalants 0.6683 0.3420
J01C Beta-lactam antibacterials, penicillins 0.5854
R03B Other drugs for obstructive airway diseases, inhalants 0.5520 0.4091
N02B Other analgesics and antipyretics 0.5332
J01F Macrolides, lincosamides and streptogramins 0.5120
N05B Anxiolytics 0.4556
S01A Anti-infective 0.4545
D07A Corticosteroids, plain 0.4018
M01A Anti-inflammatory and antirheumatic products, non-steroids 0.3990
A07C Electrolytes with carbohydrates 0.3666
D01A Antifungals for topical use 0.3452
D06A Antibiotics for topical use 0.3344
R06A Antihistamines for systemic use 0.3143 0.6159
ALL03 Allergic rhinitis 0.7213
S01G Decongestants and antiallergics 0.6773
R01A Decongestants and other nasal preparations for topical use 0.6734
ASMA Asthma 0.4222
N06B Psychostimulants, agents used for ADHD and nootropics 0.7213
N03A Antiepileptics 0.6562
PSY05 Attention deficit disorder 0.5889
PSY14 Psychosocial disorders of childhood 0.3968
NUR19 Developmental disorder 0.3857
A02B Drugs for peptic ulcers and GERD 0.3324
Abbreviations: ADHD, attention deficit hyperactivity disorder; ATC, Anatomical Therapeutic Chemical Classification; EDC, Expanded Diagnostic Clusters; GERD,
gastro-esophageal reflux disease.
Notes: Kaiser-Meyer-Olkin (KMO): 0.740; % of cumulative variance explained: 35.6%.
https://doi.org/10.1371/journal.pone.0210701.t003
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substance abuse, including alcohol consumption which represents a potential risk for DDIs
with psychotropic medication, resulting in sedation and drowsiness [19].
Factor 2 clustered a wide range of medications used for the treatment of chronic pain, such
as opioids, corticosteroids, analgesics, antipyretics, and anti-inflammatories. This pattern was
unexpectedly associated with: a) antithrombotic agents comprising both heparins and acetyl-
salicylic acid, typically used for the prevention of thromboembolism after surgery and/or long-
term stays (which can be caused by musculoskeletal pain); b) drugs for peptic ulcers, probably
prescribed to treat the gastrointestinal side effects of antithrombotics, analgesics, and cortico-
steroids [15,18,20]; and c) macrolides, penicillin antibiotics, and drugs for peptic ulcers. The
potential DDIs identified in this pattern were: a) the interaction of fentanyl with macrolides,
which increases the effect of the opioid and the risk of respiratory depression [14]; b) acetylsal-
icylic acid with diclofenac [21]; c) omeprazole with warfarin [18]; and d) omeprazole and
esomeprazole with clopidogrel [15].
Factor 3 showed a respiratory pattern with a chronic allergic component. This factor clus-
tered acute respiratory infection, allergic-rhinitis and asthma, and medications such as antihis-
tamines, antiallergics, decongestants, other nasal preparations for topical use and beta-
adrenergic agonists.
Men aged 45–65 years. This age and sex group had a KMO sampling adequacy index of
0.627. The proportion of cumulative variance explained by the patterns was 0.304. The scree
Table 4. Patterns of chronic diseases (EDC codes) and drugs (ATC codes) and factor loading scores in men aged 15–44 years. Diseases are highlighted in bold.
EDC/ATC Disease/Drug Factor 1 Factor 2 Factor 3
N06A Antidepressants 0.8979
N05C Hypnotics and sedatives 0.7614
N05A Antipsychotics 0.7482
N05B Anxiolytics 0.6522
N03A Antiepileptics 0.6442
PSY09 Depression 0.6005
PSY02 Substance use 0.4973
PSY01 Anxiety neuroses 0.4801
PSY19 Sleep disorders of nonorganic origin 0.4604
M01A Anti-inflammatory and antirheumatic products, non-steroids 0.7741
N02B Other analgesics and antipyretics 0.6115
A02B Drugs for peptic ulcers and GERD 0.5996
J01C Beta-lactam antibacterials, penicillins 0.5105
N02A Opioids 0.4920
MUS14 Low back pain 0.4663
H02A Corticosteroids for systemic use, pain 0.4642
J01F Macrolides, Lincosamides, and streptogramins 0.4037
B01A Antithrombotic agents 0.3980
RES02 Acute lower respiratory tract infection 0.3072 0.3838
R03A Adrenergics, inhalants 0.7900
R06A Antihistamines for systemic use 0.7005
ASMA Asthma 0.6227
R01A Decongestants and other nasal preparations for topical use 0.5562
ALL03 Allergic rhinitis 0.4093
Abbreviations: ATC, Anatomical Therapeutic Chemical Classification; EDC, Expanded Diagnostic Clusters; GERD, gastro-esophageal reflux disease.
Notes: Kaiser-Meyer-Olkin (KMO): 0.751; % of cumulative variance explained: 37.0%.
https://doi.org/10.1371/journal.pone.0210701.t004
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plot for this group suggested extracting four factors. However, the Heywood phenomenon
occurred, and the clinical evaluation finally recommended extracting three factors (Table 5).
The first pattern identified was very similar to Factor 1 found in younger men, but a neuro-
logical component and a pain component (i.e., lower back pain) were also present. However,
substance use was no longer present. Several DDIs were identified in this pattern: a) the use of
carbamazepine as antiepileptic drug and omeprazole [18]; b) the dispensation of antidepres-
sants and drugs for neuropathic pain [16]; and c) the combined use of benzodiazepines with
PPIs and opioids, which could increase sedation [15].
Table 5. Patterns of chronic diseases (EDC codes) and drugs (ATC codes) and factor loading scores in men aged 45–65 years. Diseases are highlighted in bold.
EDC/ATC Disease/Drug Factor 1 Factor 2 Factor 3
N06A Antidepressants 0.7887
N05B Anxiolytics 0.7326
N03A Antiepileptics 0.6613
PSY09 Depression 0.5530
N02A Opioids 0.4891
PSY01 Anxiety, neuroses 0.4447
M01A Anti-inflammatory and antirheumatic products, non-steroids 0.4166
A02B Drugs for peptic ulcers and GERD 0.3990 0.3952
PSY19 Sleep disorders of nonorganic origin 0.3594
MUS14 Low back pain 0.3367
MUS13 Cervical pain syndromes 0.3161
N02B Other analgesics and antipyretics 0.3113 0.3056
NUR21 Neurologic disorders, other 0.2959
B01A Antithrombotic agents 0.7832
HTA Hypertension 0.6610
IHD Ischemic heart disease 0.6085
DIAB Diabetes 0.5750
C09C Angiotensin II antagonists, plain 0.5396
CAR16 Cardiovascular disorders, other 0.4854
CAR09 Cardiac arrhythmia 0.4723
NUT03 Obesity 0.4283
RES04 Emphysema, chronic bronchitis, COPD 0.3380 0.3491
CAR11 Disorders of lipid metabolism 0.3296
RHU02 Gout 0.3014
R03A Adrenergics, inhalants 0.8130
R06A Antihistamines for systemic use 0.7063
RES02 Acute lower respiratory tract infection 0.5897
R01A Decongestants and other nasal preparations for topical use 0.5803
ASMA Asthma 0.5666
J01M Quinolone antibacterials 0.4548
J01F Macrolides, lincosamides, and streptogramins 0.4383
J01C Beta-lactam antibacterials, penicillins 0.3981
ALL03 Allergic rhinitis 0.3589
Abbreviations: ATC, Anatomical Therapeutic Chemical Classification; COPD, chronic obstructive pulmonary disease; EDC, Expanded Diagnostic Clusters; GERD,
gastro-esophageal reflux disease.
Notes: Kaiser-Meyer-Olkin (KMO): 0.627; % of cumulative variance explained: 30.4%. The scree plot for this group suggested extracting 4 factors. However, the
Heywood phenomenon occurred, and the clinical evaluation finally recommended extracting 3 factors.
https://doi.org/10.1371/journal.pone.0210701.t005
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Factor 2 was determined by the association among hypertension, diabetes, obesity, disor-
ders of lipid metabolism and complex cardiovascular disorders (e.g., cardiac arrhythmia and
ischaemic disease) and drugs for the treatment of these conditions. This factor also included
chronic obstructive pulmonary disease (COPD).
Factor 3 was very similar to that found in younger men but also included emphysema,
chronic bronchitis, and COPD and antibiotics (e.g., macrolides, quinolone, and penicillin).
The potential DDI identified was the use of macrolides with inhaled beta-adrenergic and anti-
histamines, producing a QT prolongation and thus increasing the risk of arrhythmia [14].
Girls aged 0–14 years. This age and sex group had a KMO sampling adequacy index of
0.732. The proportion of cumulative variance explained by the patterns was 0.332. The scree
plot and clinical discussion recommended the extraction of three factors (Table 6). The result-
ing patterns were similar to Factor 1, Factor 2 and Factor 3 identified in boys aged 0–14 years.
However, beta-adrenergic agonists and other nasal preparations for topical use were absent in
Factor 2, and Factor 3 did not comprise ADHD, which is more frequent in men than in
women at this age [22].
Women aged 15–44 years. This age and sex group had a KMO sampling adequacy index
of 0.720. The proportion of cumulative variance explained by the patterns was 0.299. The scree
plot and clinical discussion indicated that the number of factors extracted was equal to three
(Table 7). The first factor was similar to Factor 1 identified in men of the same age, but this
Table 6. Patterns of chronic diseases (EDC codes) and drugs (ATC codes) and factor loading scores in girls aged 0–14 years. Diseases are highlighted in bold.
EDC/ATC Disease/Drug Factor 1 Factor 2 Factor 3
H02A Corticosteroids for systemic use, pain 0.6427
RES02 Acute lower respiratory tract infection 0.6355
R03A Adrenergics, inhalants 0.6224
J01C Beta-lactam antibacterials, penicillins 0.5882
N02B Other analgesics and antipyretics 0.5116
J01F Macrolides, Lincosamides, and streptogramins 0.4816
N05B Anxiolytics 0.457
S01A Anti-infectives 0.4271
M01A Anti-inflammatory and antirheumatic products, non-steroids 0.4174
D07A Corticosteroids, plain 0.4097
D01A Antifungals for topical use 0.3684
A07C Electrolytes with carbohydrates 0.3648
D06A Antibiotics for topical use 0.3583
R06A Antihistamines for systemic use 0.3299 0.6105
ALL03 Allergic rhinitis 0.7546
S01G Antihistamines for systemic use 0.7419
R01A Decongestants and antiallergics 0.6744
ASMA Asthma 0.3489
N03A Antiepileptics 0.6693
N06B Psychostimulants, agents used for ADHD and nootropics 0.5403
NUR19 Developmental disorder 0.3793
A02B Drugs for peptic ulcers and GERD 0.3761
PSY14 Psychosocial disorders of childhood 0.3287
Abbreviations: ADHD, attention deficit hyperactivity disorder; ATC, Anatomical Therapeutic Chemical Classification; EDC, Expanded Diagnostic Clusters; GERD,
gastro-esophageal reflux disease.
Notes: Kaiser-Meyer-Olkin (KMO): 0.732; % of cumulative variance explained: 33.2%.
https://doi.org/10.1371/journal.pone.0210701.t006
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pattern also comprised neurological disorders and peripheral neuropathy in women, as well as
other drugs including opioids, antimigraine drugs, NSAIDs and drugs for peptic ulcers and
gastro-esophageal reflux disease (GERD). The presence of opioids was unexpected in this pat-
tern and could cause a number of DDIs because of combined use with selective serotonin
reuptake inhibitors (SSRIs), a type of antidepressant that increases the risk of serotonin syn-
drome, which in turn increases the risk of convulsions [23].
Factor 2 clustered acute respiratory infection, allergic-rhinitis and asthma with medications
such as corticoids, inhaled beta-adrenergic agonists, antipyretics, antihistamines, NSAIDS,
quinolones, macrolides, and other beta-lactam antibacterials. The DDIs identified were: a) the
use of inhaled beta-adrenergic agonists and corticosteroids, which decrease potassium levels,
Table 7. Patterns of chronic diseases (EDC codes) and drugs (ATC codes) and factor loading scores in women aged 15–44 years. Diseases are highlighted in bold.
EDC/ATC Disease/Drug Factor 1 Factor 2 Factor 3
N06A Antidepressants 0.8600
N03A Antiepileptics 0.7610
N05B Anxiolytics 0.7584
N05A Antipsychotics 0.5738
PSY09 Depression 0.5535
A02B Drugs for peptic ulcers and GERD 0.4688
N02A Opioids 0.4575
PSY01 Anxiety, neuroses 0.4333
PSY19 Sleep disorders of nonorganic origin 0.3776
N02C Antimigraine preparations 0.3742
NUR21 Neurologic disorders, other 0.3556
M01A Anti-inflammatory and antirheumatic products, non-steroids 0.3550 0.3224
NUR03 Peripheral neuropathy, neuritis 0.3093
R06A Antihistamines for systemic use 0.8167
R03A Adrenergics, inhalants 0.7087
R01A Decongestants and other nasal reparations for topical use 0.6800
S01G Decongestants and antiallergics 0.6329
ASMA Asthma 0.4935
RES02 Acute lower respiratory tract infection 0.4617
ALL03 Allergic rhinitis 0.4243
H02A Corticosteroids for systemic use, plain 0.4065
J01F Macrolides, lincosamides and streptogramins 0.3837
J01C Beta-lactam antibacterials, penicillins 0.3651
J01M Anti-inflammatory and antirheumatic products, non-steroids 0.3413
J01D Quinolone antibacterials 0.3320
N02B Other beta-lactam antibacterials 0.3169
D07A Other analgesics and antipyretics 0.3086
B03A Iron preparations 0.7959
H03C Iodine therapy 0.6469
HEM02 Iron deficiency, other deficiency anemias 0.5369
B03B Vitamin B12 and folic acid 0.4798
H03A Thyroid preparations 0.4306
END04 Hypothyroidism 0.3658
Abbreviations: ATC, Anatomical Therapeutic Chemical Classification; EDC, Expanded Diagnostic Clusters; GERD, gastro-esophageal reflux disease.
Notes: Kaiser-Meyer-Olkin (KMO): 0.740; % of cumulative variance explained: 35.6%.
https://doi.org/10.1371/journal.pone.0210701.t007
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thus increasing the risk of arrhythmia [15]; and b) the combined use of macrolides and inhaled
beta-adrenergic and antihistamines, producing a QT prolongation and thus increasing the risk
of arrhythmia [14].
Factor 3 clustered hypothyroidism and iron and other deficiency anaemias. Drugs related
to this pattern were thyroid hormone, iron therapy, iodine preparations, vitamin B12, and
folic acid. Thyroid hormone was used for hypothyroidism treatment. The presence of iron
preparations and vitamin B12 might be attributable to the treatment of autoimmune hypothy-
roidism produced by their deficiency in such patients [24–25].
Women aged 45–65 years. This age and sex group had a KMO sampling adequacy index
of 0.803. The proportion of cumulative variance explained by the patterns was 0.313. The scree
plot for this group indicated the extraction of four factors (Table 8). The first factor was similar
to Factor 1 observed in younger women but without the neurological component. The second
factor was also similar to Factor 2 observed in younger women with the absence of some medi-
cations, such as NSAIDs. Factor 3 clustered a typical metabolic syndrome with hypertension,
diabetes, obesity, and lipid metabolism disorders. The drugs related to this pattern were antith-
rombotic agents for cardiovascular prevention and ACE inhibitors for hypertension treatment
Table 8. Patterns of chronic diseases (EDC codes) and drugs (ATC codes) and factor loading scores in women aged 45–65 years. Diseases are highlighted in bold.
EDC/ATC Disease/Drug Factor 1 Factor 2 Factor 3 Factor 4
N06A Antidepressants 0.8980
N05B Anxiolytics 0.6682
PSY09 Depression 0.6131
N05C Hypnotics and sedatives 0.5592
N03A Antiepileptics 0.5406
PSY01 Anxiety, neuroses 0.4116
N02A Opioids 0.3805
PSY19 Sleep disorders of nonorganic origin 0.3618
A02B Drugs for peptic ulcers and GERD 0.3379
R03A Adrenergics, inhalants 0.7548
R06A Antihistamines for systemic se 0.7487
R01A Decongestants and other nasal preparations for topical use 0.6301
ASMA Asthma 0.5872
H02A Corticosteroids for systemic use, pain 0.4867
J01F Macrolides, lincosamides and streptogramins 0.4468
J01M Quinolone antibacterials 0.4313
ALL03 Allergic rhinitis 0.4032
J01C Beta-lactam antibacterials, penicillins 0.3853
N02B Other analgesics and antipyretics 0.3269
HTA Hypertension 0.9601
C09A ACE inhibitors, plain 0.7041
DIAB Diabetes 0.5854
NUT03 Obesity 0.5014
B01A Antithrombotic agents 0.3699
CAR11 Disorders of lipid metabolism 0.2951
A12A Calcium 0.8032
END02 Osteoporosis 0.7869
Abbreviations: ATC, Anatomical Therapeutic Chemical Classification; EDC, Expanded Diagnostic Clusters; GERD, gastro-esophageal reflux disease.
Notes: Kaiser-Meyer-Olkin (KMO): 0.803; % of cumulative variance explained: 31.3%.
https://doi.org/10.1371/journal.pone.0210701.t008
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[8]. The absence of antihyperlipidaemic drugs was due to the collinearity observed between
antihyperlipidaemics and lipid metabolism disorders, which required their exclusion from the
analysis due to statistical needs. Factor 4 comprised osteoporosis and calcium therapy.
Discussion
Main findings
A total of six clinically relevant patterns of multimorbidity and polypharmacy were found in
the young and adult population of the study, named respiratory, mental health, cardiometa-
bolic, endocrinological, osteometabolic, and mechanical pain. Differences found in their com-
position depended in part on the sex of the patient and all patterns became more complex as
age increased.
The respiratory pattern was present in all age and sex groups. It comprised a group of drugs
administered for the same category of diseases, including medications that were used to treat
complications of these illnesses (e.g., topical antifungal agents, electrolytes) or the side effects
of other drugs (e.g., anxiolytics). In the 15–44 and 45–65 age subgroups, acute-infection and
rhinitis and asthma merged in a respiratory pattern showing a chronic-allergic component in
both men and women. The associated medication pattern associated showed the addition of
quinolones, probably for infection exacerbation. In men aged 15–44 and 45–65, the use of cor-
ticoids did not appear in the pattern, but we cannot confirm that they were not prescribed.
Some therapeutic absences in women aged 45–65 years are worth noting such as NSAIDs,
which could be under prescribed because of the risk of digestive and cardiovascular side effects
[8] and antifungals for topical use, most likely due to the lower incidence of vaginal candidiasis
in postmenopausal women [8]. Treatment differences between men and women emerging
from the analysis should be further investigated.
Mental health pattern was present in all age and sex groups, varying considerably between
groups, and became more complex as age increased. In men aged 15–44 years, the mental
health pattern comprised neither neurological disorders nor peripheral neuropathy, NSAIDs,
opioids, or PPIs. The pattern included psychopathological processes such as depression, anxi-
ety, sleep disorders, psychosis, and neurosis, which are likely related to substance use, also
present in this pattern, which commonly affects men in this age range, as already reported by
Prados-Torres et al. [12]. Substance abuse includes alcohol consumption, which represents a
potential risk for DDIs with psychotropic medication, resulting in sedation and drowsiness
[19]. The neuro-psychiatric pattern in this sex and age group could thus be due to substance
abuse. Other diseases could also be consequence of some type of dependency. This causal
hypothesis is supported by the fact that this pattern did not appear in women, in which toxic
substance use occurs less frequently, as supported by the bibliography [12].
A consistent cardiometabolic pattern is described in our study, with a composition already
reported in the bibliography [12]. This pattern appeared only in men and women aged 45–65
years. In women, this pattern describes a typical metabolic syndrome. In men, other associated
conditions were detected, such as COPD, gout and complex cardiovascular disorders, possibly
due to increased cardiovascular risk in men, together with increased incidence of ischemic
heart and cerebrovascular diseases [8]. The presence of emphysema, chronic bronchitis, and
COPD can be related to the association between the cardiac and respiratory domains already
described and supported in the literature [20]. The presence of antithrombotic agents in men
could be related to the prevention of cardiovascular diseases and to the treatment of ischemic
disease and arrhythmia. The use of PPIs is widely recommended for patients taking antiplatelet
agents [8]. However, we did not find PPIs in women treated with antithrombotic agents,
which was unexpected and cannot be further explained. Indeed, the absence of PPIs was
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already observed in a previous polypharmacy cluster analysis performed in our study cohort
[8]. On the other hand, the use of different antihypertensive drugs in men and women was not
justified from a clinical point of view [26]. It is worth highlighting the different pharmacologi-
cal approaches followed in middle-aged men and women in our study, as the use of different
antihypertensive drugs cannot be supported scientifically [26–27].
In men aged 15–44 years, the presence of a mechanical-pain pattern was evident. Mino-
Leo´n et al. [20] recently observed that the associations among the vascular, upper gastroin-
testinal, and musculoskeletal domains could be a consequence of two factors. First, changes
that occur in the connective tissue with ageing, have been linked to a low grade of inflam-
mation. Second, side effects are related to the pharmacological treatment of the diseases
included in the musculoskeletal pattern [20], such as the treatment of gastrointestinal dis-
ease caused by NSAIDs, corticosteroids, and antithrombotic agents [15,18,20] It is notewor-
thy that the pattern also comprised macrolides, penicillin antibiotics, and drugs for peptic
ulcers, all of which are usually used for the eradication of Helicobacter pylori (H. pylori).
Indeed, NSAID-naïve users should be tested for the presence of H. pylori infection and, if
positive, receive eradication therapy before NSAID use, a practice that is well accepted and
supported by strong evidence [28].
In women aged 15–44 and 45–65 years we identified an endocrinological and an osteome-
tabolic pattern, respectively. The presence of iron and other deficiency anaemia observed in
women aged 15–44 years could be due to conditions such as menstruation and pregnancy in
which the use of the abovementioned preparations is more necessary. The dispensation of cal-
cium appeared alone in the osteometabolic pattern. The combined use of calcium and other
osteoporosis treatments shows certain protective effect for the prevention of hip and non-ver-
tebral fractures. Although the use of Vitamin D is recommended for osteoporosis, this medica-
tion did not appear in this pattern, which is in agreement with the current deficiency reported
for this vitamin [29].
Several examples of potential DDIs at increased risk of adverse health outcomes were
observed in our study, including potential DDIs in the respiratory pattern for the different age
subgroups, such as: a) the use of inhaled beta-adrenergic agonists and corticosteroids, which
decreased potassium levels, thus increasing the risk of arrhythmia [15]; b) the use of macro-
lides with inhaled beta-adrenergic and antihistamines, producing a QT prolongation and thus
increasing the risk of arrhythmia [14]; and c) the combined use of NSAIDs and corticoids in
the 0–14 age subgroup, which can increase the gastrointestinal risk [15]. In the mental health
pattern, we also reported DDIs such as: a) the combined use of carbamazepine for epilepsy
and methylphenidate for the treatment of ADHD which may decrease the effect of methylphe-
nidate [14]; c) antidepressants and drugs for neuropathic pain [16]; and d) the combined use
of benzodiazepines with PPIs and opioids, which increases sedation [15].
Other associations described in the present study cannot be fully rationalized and should be
further investigated as they may give new clues to a better understanding of the relationship
between multimorbidity and polypharmacy.
Strengths and limitations
To our knowledge, this is the first large-scale population study exploring the systematic associ-
ation among chronic diseases and dispensed drugs. The large population size of the EpiChron
Cohort, which has already served as a basis for several pharmaco-epidemiological studies [30–
32], together with the quality of data, resulted in reliable and representative results compared
to those based only on medical records or drug use surveys. Furthermore, the goodness-of-fit
values of the obtained models (i.e., KMO sampling adequacy index and proportion of
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cumulative variance explained) indicated that factor analysis is an appropriate statistical tech-
nique to achieve the aims of the study in the target population [12].
However, one of the most important methodological limitations of this study concerns the
impossibility of including some drugs in the analyses due to multicollinearity with specific dis-
eases, thus leading to the absence of specific drugs that would be, a priori, expected in some
patterns. The issue of multicollinearity was also responsible for excluding the population aged
>65 years from the analysis, which limited the comprehensiveness of the study. Further inves-
tigations using complementary methodological approaches are needed to identify the system-
atic association among chronic diseases and drugs in the elderly, in which potential
interactions among drugs and diseases would be more relevant due to the higher burden of
chronic diseases and medications.
Several hypotheses have been arisen regarding the clinical explanation that underlies the six
multimorbidity and polypharmacy patterns revealed in this study. However, they must be
interpreted with caution since the study design (i.e., cross-sectional) does not allow the estab-
lishment of the sequence in which diseases and medications cluster within a pattern. Longitu-
dinal studies would be necessary to corroborate the suggested causal associations and elucidate
the associations that could not be explained in the present study. Another limitation of the
study stems from the lack of information on the use of over-the-counter (OTC) medications,
which could lead to underestimation of the actual drug use.
Comparison with other studies
In 2012, a study based on exploratory factor analysis conducted in patients over 14 years old
supported the existence of mechanical-obesity, metabolic, neurovascular, liver disease, psychi-
atric-substance abuse, anxiety, and depression-related patterns [12]. These results largely coin-
cide with our findings and support the existence of the multimorbidity patterns described. The
main difference with our study is that we analysed multimorbidity only in populations aged up
to 65 years, similar to two Spanish studies conducted with information obtained from elec-
tronic medical records and the primary care pharmacy database in 2008 [8,12]. One of the
studies stablished the existence of multimorbidity patterns [12] and the other one demon-
strated the existence of non-random associations in drug prescription, resulting in patterns of
polypharmacy [8].
The present study can be considered more exhaustive because it connects multimorbidity
and polypharmacy patterns and evidences the existence of some unexpected systematic associ-
ations among chronic diseases and drugs, as well as potential DDIs and prescribing cascades
described in multimorbid patients.
Implications for health systems
This study validates part of the results obtained from a previous factor analysis study exploring
associations between drugs [8]. The discovery of non-random associations among drugs and
diseases could help in the development and/or adaptation of clinical guidelines to chronic
patients with multimorbidity who are taking multiple drugs. Understanding the way in which
drugs are associated with multimorbidity will bring about a better understanding of polyphar-
macy management allowing us to better identify inappropriate polypharmacy. This has been
urgently requested by the scientific community [33–34].
Conclusion
This study revealed the existence of systematic associations among chronic diseases and dis-
pensed drugs in both men and women up to 65 years of age, showing that they may occur at
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all ages, including children, and that they have a lifelong evolution. Six patterns of multimor-
bidity and polypharmacy were identified, named respiratory, mental health, cardiometabolic,
endocrinological, osteometabolic, and mechanical-pain. The clinical interpretation of such
patterns suggests that, apart from some expected associations related to the pharmacological
treatment of diseases, the existence of drug-drug interactions and prescribing cascades may be
a potential underlying factor for some of the associations identified among chronic diseases
and drugs. The evidence of unexpected systematic associations between diseases and drugs in
the patterns may help in the early identification of potential interactions in multimorbid
patients with a high risk of adverse health outcomes due to polypharmacy.
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